Nanotech Systems Inc.
Nanotech Systems Inc.: Dr. Terrance Owen Appointed as CEO
Nanotech Systems Inc. / Key word(s): Change of Personnel FWB:N95 July 24, 2012 Dr. Terrance Owen Appointed as CEO Vancouver, BC, Canada – Nanotech Systems, Inc. (‘NSI’ or ‘the Company’) is pleased to announce the appointment of Dr. Terrance Owen as Chief Executive Officer of the company effective May 1, 2012. Dr. Owen was awarded a Ph.D. in Zoology by the University of British Columbia UBC in 1974 and a M.B.A. by Simon Fraser University in 1991. He is the co-founder and has been the President and CEO of ALDA Pharmaceuticals Corp., which has developed novel, patented, OTC infection control therapeutics for topical use, since 2000. From 1980 to 2002, he was the President of Helix Biotech , which provided DNA testing services for paternity, immigration and forensic cases across Canada. From 1995 to 1998, he was also the President of Helix BioPharma Corp., a company focused on drug delivery, discovery, development, distribution and licensing. Dr. Owen has 25 years of executive experience with publicly-traded life sciences companies in Canada and the US. He will be responsible for maintaining the Company’s listing on the Frankfurt Stock Exchange (‘the FSE’) which is eliminating its First Quotation Board and requiring companies to meet the Entry Standard listing requirements by December 15, 2012. Dr. Owen states, ‘To meet the new listing requirements for the Frankfurt Exchange, we have decided that a co-listing on the TSX Venture Exchange or another ‘like’ exchange is the best approach. We have also identified attractive pharmaceutical prospects for NSI and will be immediately pursuing the development of a new business plan and the documentation that is required to achieve a co-listing. While that work is in progress, our goal is to expand revenues as quickly as possible and establish a pipeline of additional products for the Company’. About Nanotech Systems, Inc. This press release is for informational purposes only and does not constitute, or form part of, an offer to buy or a solicitation of any offer to sell any securities in any jurisdiction nor shall it (or any part of it), or the fact of its distribution, form the basis of or be relied on in connection with any contract therefore. End of Corporate News 24.07.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
178955 24.07.2012 |